Bulging order book for bioconjugates lifts WuXi XDC profits
The provider of outsourced pharmaceutical services has delivered unexpectedly strong half-year earnings and has launched its first overseas production hub Key Takeaways: WuXi XDC began operations in August at a…
Cancer drug sales power up Kelun-Biotech’s profit engine
The firm made more money from precision oncology treatments than from licensing deals in the first half, after gaining insurance coverage for its core drugs in China Key Takeaways: The…
Cash-strapped Sirnaomics seeks lifeline in cosmetic treatments
The biotech is suing its former CEO over an ill-fated $20 million investment as it pursues a short-term pivot from skin cancer drugs to body-contouring therapies Key Takeaways: After the…
Alphamab seals $2.2 billion licensing deal with AI biotech
The Chinese drug firm has chosen to partner with an AI specialist rather than Big Pharma on a dual-target cancer therapy, netting an upfront payment of $125 million Key Takeaways:…
Angelalign finds new smile in central procurement era
Despite swallowing lower prices under a government procurement program, the leading ‘invisible’ dental braces maker posted strong profit and revenue gains in the first half of 2026 Key Takeaways: Angelalign’s…
PrimeGenX looks to a Hong Kong IPO as a cure for its cash woes
The developer of anti-inflammatory treatments will need to persuade investors to look past its balance sheet problems and its narrow pipeline of products Key Takeaways: The company is making a…
Traditional Chinese medicine leader Yuyantang finds tonic in aging population
The company has filed for a Hong Kong IPO, thriving on China’s growing silver economy and a steady stream of government policies supporting traditional Chinese medicine Key Takeaways: Yuyantang has…
